| Heterogeneous ribosomes preferentially translate distinct subpools of mRNAs genome-wide Z Shi, K Fujii, KM Kovary, NR Genuth, HL Röst, MN Teruel, M Barna Molecular cell 67 (1), 71-83. e7, 2017 | 569 | 2017 |
| Differential requirements for eIF4E dose in normal development and cancer ML Truitt, CS Conn, Z Shi, X Pang, T Tokuyasu, AM Coady, Y Seo, ... Cell 162 (1), 59-71, 2015 | 350 | 2015 |
| Translating the genome in time and space: specialized ribosomes, RNA regulons, and RNA-binding proteins Z Shi, M Barna Annual review of cell and developmental biology 31, 31-54, 2015 | 216 | 2015 |
| Translation control of the immune checkpoint in cancer and its therapeutic targeting Y Xu, M Poggio, HY Jin, Z Shi, CM Forester, Y Wang, CR Stumpf, L Xue, ... Nature medicine 25 (2), 301-311, 2019 | 212 | 2019 |
| FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer M Oliveira, C Saura, P Nuciforo, I Calvo, J Andersen, JL Passos-Coelho, ... Annals of Oncology 30 (8), 1289-1297, 2019 | 126 | 2019 |
| SRSF1 and SRSF9 RNA binding proteins promote Wnt signalling‐mediated tumorigenesis by enhancing β‐catenin biosynthesis Y Fu, B Huang, Z Shi, J Han, Y Wang, J Huangfu, W Wu EMBO molecular medicine 5 (5), 737-750, 2013 | 105 | 2013 |
| Repression of germline RNAi pathways in somatic cells by retinoblastoma pathway chromatin complexes X Wu, Z Shi, M Cui, M Han, G Ruvkun PLoS genetics 8 (3), e1002542, 2012 | 75 | 2012 |
| High-throughput sequencing reveals extraordinary fluidity of miRNA, piRNA, and siRNA pathways in nematodes Z Shi, TA Montgomery, Y Qi, G Ruvkun Genome research 23 (3), 497-508, 2013 | 74 | 2013 |
| Pervasive translational regulation of the cell signalling circuitry underlies mammalian development K Fujii, Z Shi, O Zhulyn, N Denans, M Barna Nature communications 8 (1), 14443, 2017 | 67 | 2017 |
| Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation A Sacher, P LoRusso, MR Patel, WH Miller Jr, E Garralda, MD Forster, ... New England Journal of Medicine 389 (8), 710-721, 2023 | 56 | 2023 |
| Multiple small RNA pathways regulate the silencing of repeated and foreign genes in C. elegans SEJ Fischer, Q Pan, PC Breen, Y Qi, Z Shi, C Zhang, G Ruvkun Genes & Development 27 (24), 2678-2695, 2013 | 46 | 2013 |
| Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors JK Lee, S Sivakumar, AB Schrock, R Madison, D Fabrizio, O Gjoerup, ... NPJ Precision Oncology 6 (1), 91, 2022 | 37 | 2022 |
| Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAFV600-mutated Metastatic Melanoma Y Yan, MJ Wongchenko, C Robert, J Larkin, PA Ascierto, B Dréno, M Maio, ... Clinical Cancer Research 25 (11), 3239-3246, 2019 | 33 | 2019 |
| The mevalonate pathway regulates microRNA activity in Caenorhabditis elegans Z Shi, G Ruvkun Proceedings of the National Academy of Sciences 109 (12), 4568-4573, 2012 | 33 | 2012 |
| Functional mapping of AKT signaling and biomarkers of response from the FAIRLANE trial of neoadjuvant ipatasertib plus paclitaxel for triple-negative breast cancer Z Shi, J Wulfkuhle, M Nowicka, RI Gallagher, C Saura, PG Nuciforo, ... Clinical Cancer Research 28 (5), 993-1003, 2022 | 27 | 2022 |
| OA03. 04 phase IA study to evaluate GDC-6036 monotherapy in patients with Non-small Cell Lung Cancer (NSCLC) with KRAS G12C mutation A Sacher, MR Patel, WH Miller, J Desai, E Garralda, S Bowyer, TW Kim, ... Journal of Thoracic Oncology 17 (9), S8-S9, 2022 | 22 | 2022 |
| PI3K/AKT pathway biomarkers analysis from the phase III IPATential150 trial of ipatasertib plus abiraterone in metastatic castration-resistant prostate cancer JS De Bono, C Sweeney, S Bracarda, CN Sternberg, KN Chi, D Olmos, ... J Clin Oncol 39 (6_suppl), 13-3, 2021 | 22 | 2021 |
| A stem cell roadmap of ribosome heterogeneity reveals a function for RPL10A in mesoderm production NR Genuth, Z Shi, K Kunimoto, V Hung, AF Xu, CH Kerr, GC Tiu, ... Nature communications 13 (1), 5491, 2022 | 18 | 2022 |
| Biomarker analysis of the phase III IPATential150 trial of first-line ipatasertib (Ipat) plus abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC). Z Shi, C Sweeney, S Bracarda, CN Sternberg, KN Chi, D Olmos, ... Journal of Clinical Oncology 38 (6_suppl), 182-182, 2020 | 16 | 2020 |
| Dual Regulation of the lin-14 Target mRNA by the lin-4 miRNA Z Shi, G Hayes, G Ruvkun PloS one 8 (9), e75475, 2013 | 16 | 2013 |
Maria BarnaAssociate Professor of Genetics, Stanford UniversityBestätigte E-Mail-Adresse bei stanford.edu
